Medulloblastoma

Oncology·MeSH: Medulloblastoma

Prevalence

5.0 / 100K

37 drugs in development·12 companies·13 clinical trials

Drug Pipeline by Phase

Approved(1)

Drug	Company
carmustine	Amneal Pharmaceuticals, Inc. (AMRX)

Phase 3(9)

Drug	Company
A10 and AS2-1 Antineoplaston	BURZYNSKI RESEARCH INSTITUTE INC (BZYR)
Antineoplastons (A10 & AS2-1)	BURZYNSKI RESEARCH INSTITUTE INC (BZYR)
Antineoplastons (A10 and AS2-1)	BURZYNSKI RESEARCH INSTITUTE INC (BZYR)
Etoposide	Assertio Holdings, Inc. (ASRT)
Filgrastim	Assertio Holdings, Inc. (ASRT)
lomustine	CG Oncology, Inc. (CGON)
Lomustine	Filana Therapeutics Inc. (FLNA)
Sodium Thiosulfate	Filana Therapeutics Inc. (FLNA)
Vincristine	Assertio Holdings, Inc. (ASRT)

Phase 2(16)

Drug	Company
Celecoxib	AIM ImmunoTech Inc. (AIM)
Celecoxib	Black Diamond Therapeutics, Inc. (BDTX)
Cytarabine	AIM ImmunoTech Inc. (AIM)
Etoposide	Structure Therapeutics Inc. (GPCR)
Etoposide	AIM ImmunoTech Inc. (AIM)
etoposide phosphate	AIM ImmunoTech Inc. (AIM)
Fenofibric acid	Black Diamond Therapeutics, Inc. (BDTX)
Fenofibric acid	AIM ImmunoTech Inc. (AIM)
Pegfilgrastim	Assertio Holdings, Inc. (ASRT)
Thalidomide	Black Diamond Therapeutics, Inc. (BDTX)
Thalidomide	AIM ImmunoTech Inc. (AIM)
Topotecan	ENANTA PHARMACEUTICALS INC (ENTA)
Topotecan	Assertio Holdings, Inc. (ASRT)
Topotecan	Structure Therapeutics Inc. (GPCR)
TTRNA-DCs	UNITED THERAPEUTICS Corp (UTHR)
TTRNA-xALT	UNITED THERAPEUTICS Corp (UTHR)

Phase 1(2)

Drug	Company
group a standard-of-care backbone therapy	GH Research PLC (GHRS)
Vincristine	Structure Therapeutics Inc. (GPCR)

Phase 4(9)

Drug	Company
Induction	Merus N.V. (MRUS)
Induction	Filana Therapeutics Inc. (FLNA)
Induction	Structure Therapeutics Inc. (GPCR)
Single Cycle Intensive Chemotherapy	Filana Therapeutics Inc. (FLNA)
Single Cycle Intensive Chemotherapy	Structure Therapeutics Inc. (GPCR)
Tandem 3 Cycle Intensive Chemotherapy	Filana Therapeutics Inc. (FLNA)
Tandem 3 Cycle Intensive Chemotherapy	Structure Therapeutics Inc. (GPCR)
Vincristine	Filana Therapeutics Inc. (FLNA)
Vincristine Sulfate Liposome	Filana Therapeutics Inc. (FLNA)

BioSniper tracks 37 drugs in development for Medulloblastoma across 12 companies.

There are 13 clinical trials targeting Medulloblastoma tracked by BioSniper.

The estimated prevalence of Medulloblastoma is approximately 5.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.